If glucose homeostasis can be corrected through diet, sleep, and exercise, then GLP-1 agonists and SGLT2 inhibitors may not be targeting fundamental aging processes.

“Well, the the GLP um drugs uh and SGLT2 I think are interesting. I don't think we have the data right now, but it's definitely again I don't know in people that are You know, if you're obese, I need Yeah. Okay. So, let let me restate the question. If if we if we just took a population of middle-aged healthy individuals and we we could design an experiment where you had the placebo arm, the metformin arm, the rapamy arm, the SGLT2 inhibitor arm, and the GLP1 agonist arm. What is your prediction in length of life or additional years of life given in that six arm study or whatever it is?”